SCHEMBL4072697

SCHEMBL4072697

COc1cc(/C=C(/C#N)S(=O)(=O)c2ccc(Cl)cc2)cc(I)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.54
ALDH1A1 P00352 5/20 0.49
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
HPGD P15428 4/20 0.49
KDM4E B2RXH2 4/20 0.49
MAPT P10636 4/20 0.49
ALOX15 P16050 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HSD17B10 Q99714 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
POLB P06746 2/20 0.49
ALPG P10696 2/20 0.49
ALOX12 P18054 2/20 0.49
RGS12 O14924 2/20 0.49
GMNN O75496 2/20 0.49
USP2 O75604 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4072693 1.00 EGFR (0.54) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4072698 1.00 EGFR (0.54) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4070546 0.92 EGFR (0.60) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4070549 0.92 EGFR (0.60) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4070550 0.92 EGFR (0.60) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4072664 0.79 PKM (0.50) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4077040 0.79 PKM (0.50) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4072666 0.79 PKM (0.50) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4072088 0.77 EGFR (0.56) EGFRALDH1A1MEN1KMT2AHPGD
SCHEMBL4073611 0.77 EGFR (0.56) EGFRALDH1A1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1625112-B1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY HIGH POINT PHARMACEUTICALS LLC (US) 2009-07-22 EP claimed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US claimed
EP-1625112-B1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY HIGH POINT PHARMACEUTICALS LLC (US) 2009-07-22 EP disclosed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128662-A1 Novel compounds for treatment of obesity GPR119, FABP4, HSD17B4 EGFR 4687/4885ALDH1A1 66/4885MEN1 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.